The American Society of Clinical Oncology (the Society) is governed by a volunteer Board of Directors (including five Board officers) elected by ASCO’s member oncologists. The ASCO Chief Executive Officer serves on the Board as well. Elected Board members are cancer physicians and clinical researchers who volunteer their time to ASCO. Board members are not paid for their service, although their institutions receive stipends to partially cover the time and administrative resources dedicated to ASCO.
View the Disclosures for the Society Board of Directors at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to our COI team.

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.
Read Dr. Hudis’ Q&A on ASCO Connection.
View current ASCO disclosure here.

Dr. Winer has been elected to serve as the ASCO President in 2022-2023. He is the Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven. Before then, he served as the chief clinical development officer, senior vice president for medical affairs, Director of the Dana-Farber/Harvard SPORE in Breast Cancer, and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He has also served as a professor of medicine at Harvard Medical School. Dr. Winer served on the ASCO Board of Directors from 2011 to 2015, and has served as chair of the ASCO Government Relations Committee, Cancer Communications Committee, and Health Services Research Committee, among numerous volunteer roles. He was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture in 2017 and the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.
View current ASCO disclosure here.

Dr. Schuchter is chief of the Division of Hematology-Oncology at the Abramson Cancer Center at the University of Pennsylvania, director of the Tara Miller Melanoma Center at the Abramson Cancer Center, and the Madlyn and Leonard Abramson Professor of Clinical Oncology at the Perelman School of Medicine of the University of Pennsylvania. Dr. Schuchter is a clinical investigator in the area of melanoma and has a strong commitment to mentorship. Dr. Schuchter served on the ASCO Board of Directors from 2009 to 2012. She has served on numerous ASCO committees, including terms as chair of Annual Meeting Scientific Program Committee, Cancer Research Committee, and Cancer Communications Committee, and as an editor on the Journal of Clinical Oncology Editorial Board. In 2019, she was recognized with the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award from Conquer Cancer, the ASCO Foundation.
View current ASCO disclosure here.

Dr. Vokes specializes in head and neck and lung cancers. He is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance ( formerly Cancer and Leukemia Group B ) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, and a member of the Conquer Cancer Development and Fundraising Committee, and the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.
View current ASCO disclosure here

Dr. Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan where she is currently Professor with tenure in Radiation Oncology. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds.
Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.
Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching awards from the University of Michigan and multiple national organizations. Honors include receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists’ Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. Most Recently, she was the recipient of the 2021 Association of Community Cancer Centers Annual Achievement Award and the 2021 American Society for Radiation Oncology Gold Medal Award.
View current ASCO disclosure here.

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at Brigham and Women’s Hospital, Associate Chair of Research for the Department of Surgery, and co-leader of the Breast Program at Dana-Farber / Harvard Cancer Center. She has previously served on ASCO’s Annual Meeting Scientific Program Committee and as chair of the Conquer Cancer Grants Selection Committee and chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Scientific Program Committee. Dr. Mittendorf is currently the Treasurer-Elect and will serve as the Treasurer of the Society Board of Directors beginning June 2022.
View current ASCO disclosure here.

Dr. Plimack serves as at the Deputy Director of Fox Chase Cancer Center in Philadelphia. She is a professor of medical oncology and the director of genitourinary clinical research at the center. She is a past member and track chair of the ASCO Scientific Program Committee, Genitourinary (Non-Prostate) Cancer track. She serves as a member on the Board’s Finance Committee and is the Board Liaison to the Cancer Communications Committee. Dr. Plimack received a Conquer Cancer Merit Award at the 2008 Genitourinary Cancers Symposium.
Read Dr. Plimack's Q&A on ASCO Connection.
View current ASCO disclosure here.

Dr. Asirwa is the chief oncologist and hematologist and the CEO/executive director of the International Cancer Institute in Kenya. He is a member of the ESMO/ASCO Task Force for Global Curriculum for Training in Medical Oncology, among other past volunteer appointments. He is currently leading various cancer care access, innovation and personalized medicine programs in sub-Saharan Africa.
View current ASCO disclosure here.

Dr. Basch is chief of the division of oncology at the University of North Carolina and physician-in-chief of the North Carolina Cancer Hospital. He is the Richard M Goldberg Distinguished Professor in Medical Oncology and professor of health policy & management. He serves as director of the cancer outcomes research program at UNC Lineberger Comprehensive Cancer Center, as associate editor at Journal of the American Medical Association, and on the editorial board of the Journal of Oncology Practice. He has previously served on the NCI Board of Scientific Advisors, on the Methodology Committee of PCORI, as chair of the ASCO Clinical Practice Guidelines Committee, the CancerLinQ Advisory Group, the Annual Meeting Education Committee, and the Quality of Care Council.
Read Dr. Basch’s Q&A on ASCO Connection.
View current ASCO disclosure here.

Dr. Carey is Chief of Hematology/Oncology, Associate Director of Clinical Sciences, and the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina Lineberger Comprehensive Cancer Center. She is also Physician-In-Chief of the N.C. Cancer Hospital. Dr. Carey is a member of ASCO’s Breast Cancer Guideline Advisory Group. She previously served the Society as chair of the Nominating Committee, chair of the Professional Development Committee, track leader of the Annual Meeting Education Committee, and a member of the Journal of Clinical Oncology editorial board.
View current ASCO disclosure here

Dr. Henderson is a professor of pediatrics, Division Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation and director of the Childhood Cancer Survivor Center at the University of Chicago, and co-leader of the cancer prevention and control program for the University of Chicago Comprehensive Cancer Center. She is a graduate of the 2018 President Leadership Scholars program and a 2015 graduate of the ASCO Leadership Development Program. Dr. Henderson is the chair of the ASCO Adolescent and Young Adult (AYA) Survivorship Work Group and a past member of several ASCO committees, including the Government Relations Committee, the Survivorship Guideline Advisory Group, the Conquer Cancer Grants Selection Committee and Osteoporosis in Survivors of Adult Cancers Expert Panel. She is the past chair of the Cancer Survivorship Committee, a member of the Society Board’s Audit Committee and a liaison to the Conquer Cancer Grants Selection Committee.
View current ASCO disclosure here.

Dr. Hendricks is a practicing medical oncologist specializing in breast cancer genetics, screening, and treatment at Maryland Oncology Hematology PA. She is immediate past chair of the Government Relations Committee, past chair of the ABIM-ASCO Breast Cancer Exam Subcommittee, and a member of the Practice Quality Improvement Steering Group, among other volunteer service. Dr. Hendricks was honored as Advocate of the Year by the Association for Clinical Oncology in 2019.
View current ASCO disclosure here.

Dr. Chavez Mac Gregor is an Associate Professor in the Department of Health Services Research and an Associate Professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. She is Co-Chair of the ASCO Breast Cancer Guideline Advisory Group and a member of the Resource-Stratified Guideline Advisory Group. She has served as Chair of the Clinical Practice Committee and the Methodology Subcommittee, along with many other volunteer roles, including serving as a grant reviewer and as a member of the Women’s Networking Center Task Force. She is a 2018–2019 participant in ASCO’s Leadership Development Program, and is the recipient of several Merit Awards and the Breast Cancer Advanced Clinical Research Award from Conquer Cancer, the ASCO Foundation.
View current ASCO disclosure here.

Dr. Owonikoko is the Chief of the Division of Hematology and Oncology, co-Leader of the Cancer Therapeutics Program, and Associate Director for Translational Research at the University of Pittsburgh Medical Center Hillman Cancer Center. He is a Professor in the Department of Medicine and the Stanley M. Marks – OHA Endowed Chair in Hematology/Oncology Leadership at the University of Pittsburgh. He previously served as the Director of Thoracic Oncology, Co-Leader of the Discovery and Developmental Therapeutics Research Program, and Chair of the Aerodigestive Malignancies Working Group at Winship Cancer Institute. Dr. Owonikoko has chaired the ASCO Annual Meeting Education Committee; has served as track leader and member of the Annual Meeting Scientific Program and Education Committees; and as a mentor in ASCO’s Diversity Mentoring Program. He is a 2015–2016 participant in ASCO’s Leadership Development Program.
View current ASCO disclosure here.

Dr. Partridge is a practicing medical oncologist and clinical researcher. She is vice chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as director of the Adult Survivorship Program and co-founder and director of the Program for Young Women with Breast Cancer. She is a professor at Harvard Medical School and holds the Eric P. Winer Chair in Breast Cancer Research at Dana-Farber. Dr. Partridge has sought to reduce morbidity and mortality from cancer through innovative research, guideline development, dedicated educational efforts, mentoring junior colleagues, and direct patient care. She has led studies focused on cancer disparities, risk perceptions, decision-making, quality of life, adherence with anti-cancer therapy, and cancer survivorship. She is particularly committed to research to reduce disparities in outcomes among young women with breast cancer. Dr. Partridge has served on numerous ASCO committees and initiatives including as Chair of the Clinical Practice Guidelines Committee as well as Chair of the Scientific Program Committee for the 2018 Annual Meeting. She chaired the Center for Disease Control’s Advisory Committee on Breast Cancer in Young Women from 2010-2017 and is leading national clinical research endeavors as co-Chair of the Alliance for Clinical Trials in Oncology Breast Committee and a member of the NCI Breast Cancer Steering Committee. Dr. Partridge is a recipient of a Champions of Change award from the U.S. White House, the AACR Outstanding Investigator Award for Breast Cancer, and ASCO’s Ellen L. Stovall Award for Advancement of Cancer Survivorship Care from Conquer Cancer.
View current ASCO disclosure here.

Dr. Rodriguez is a medical oncologist and hematologist, Vice President of Clinical Research at South Texas Oncology and Hematology, PA at the START Center for Cancer Care, and Co-Manager of South Texas Accelerated Research Therapeutics (START). She has served as a member of the ASCO Government Relations Committee, State Affiliate Council, and COVID-19 Road to Recovery Task Force, among other volunteer roles. She was honored as an ASCO Advocacy Champion in 2019 and 2020. Dr. Rodriguez is Past President and Board member of the Texas Society of Clinical Oncology (TxSCO), an ASCO State Affiliate.
View current ASCO disclosure here.

Dr. Soto Pérez is a geriatric oncologist and researcher in the Department of Geriatrics at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City. On the Board, he serves as a liaison to the ASCO Education Council, and is a member of the Society’s Finance Committee. He also currently serves on several ASCO committees, including the Journal of Global Oncology Editorial Board, Social Media Working Group, Diversity and Inclusivity Task Force, Technology Research Group, and Publishing Research Group. He has previously served on the AM Education Committee and the Grants Selection Committee. He received a 2019 Conquer Cancer Career Development Award. Previously, Dr. Soto has served on several other ASCO research groups and advisory panels, contributed to the ASCO Connection and ASCO Daily News, and was selected for a Journal of Global Oncology Editorial Fellowship.
Read Dr. Soto’s Q&A on ASCO Connection.
View current ASCO disclosure here.

Dr. Thompson is a medical oncologist and hematologist. He currently serves as the Vice President of Clinical Partnerships with Tempus Labs, Inc. He previously served as medical director for the Early Phase Cancer Research Program, co-PI of the Aurora NCORP as well as the co-director of Oncology Precision Medicine Program at Advocate Aurora Health. He currently maintains a hematology clinic at Aurora. He is a graduate of ASCO’s Leadership Development Program, has served as chair of the ASCO Annual Meeting Education Committee and the Research Community Forum Council, and is a current member of several ASCO volunteer groups.
Read Dr. Thompson’s Q&A on ASCO Connection.
View current ASCO disclosure here.

Dr. Winkfield is the executive director of the Meharry-Vanderbilt Alliance and a radiation oncologist at Vanderbilt University Medical Center. She is chair of the ASCO Diversity and Inclusivity Task Force. Previously, Dr. Winkfield was a member of the ASCO Government Relations Committee and the ASCO-ACCC Collaboration to Increase Participation of Racial & Ethnic Minority Populations in Cancer, and was an associate editor for Cancer.Net, ASCO’s patient information website. Dr. Winkfield is a past participant in the ASCO Leadership Development Program and was recently appointed by President Joe Biden to serve on the National Cancer Advisory Board.
View current ASCO disclosure here.

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.
Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.
Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society's Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
View current ASCO disclosure here.